- Home
- RDZN vs IVVD Comparison
RDZN vs IVVD Comparison
Compare RDZN & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDZN
- IVVD
- Stock Information
- Founded
- RDZN 2015
- IVVD 2020
- Country
- RDZN United States
- IVVD United States
- Employees
- RDZN N/A
- IVVD N/A
- Industry
- RDZN Blank Checks
- IVVD Biotechnology: Pharmaceutical Preparations
- Sector
- RDZN Finance
- IVVD Health Care
- Exchange
- RDZN Nasdaq
- IVVD Nasdaq
- Market Cap
- RDZN 79.4M
- IVVD 69.0M
- IPO Year
- RDZN N/A
- IVVD 2021
- Fundamental
- Price
- RDZN $1.00
- IVVD $0.74
- Analyst Decision
- RDZN Strong Buy
- IVVD Strong Buy
- Analyst Count
- RDZN 2
- IVVD 3
- Target Price
- RDZN $5.00
- IVVD $5.85
- AVG Volume (30 Days)
- RDZN 678.3K
- IVVD 1.3M
- Earning Date
- RDZN 08-12-2025
- IVVD 08-13-2025
- Dividend Yield
- RDZN N/A
- IVVD N/A
- EPS Growth
- RDZN N/A
- IVVD N/A
- EPS
- RDZN N/A
- IVVD N/A
- Revenue
- RDZN $44,296,098.00
- IVVD $36,688,000.00
- Revenue This Year
- RDZN $39.09
- IVVD $446.60
- Revenue Next Year
- RDZN $65.61
- IVVD $112.63
- P/E Ratio
- RDZN N/A
- IVVD N/A
- Revenue Growth
- RDZN N/A
- IVVD N/A
- 52 Week Low
- RDZN $0.68
- IVVD $0.35
- 52 Week High
- RDZN $2.99
- IVVD $2.74
- Technical
- Relative Strength Index (RSI)
- RDZN 48.19
- IVVD 48.03
- Support Level
- RDZN $0.98
- IVVD $0.70
- Resistance Level
- RDZN $1.07
- IVVD $0.77
- Average True Range (ATR)
- RDZN 0.09
- IVVD 0.05
- MACD
- RDZN -0.00
- IVVD -0.00
- Stochastic Oscillator
- RDZN 26.67
- IVVD 45.94
About RDZN Roadzen Inc.
Roadzen Inc is an insurance technology company on a mission to transform global auto insurance powered by advanced AI. Its clients comprise major insurers, fleets, and carmakers to small fleets, brokers, and insurance agents that use Roadzen's technology to build new products, sell insurance, process claims, and improve road safety. The company's work in telematics and computer vision has earned recognition as an AI innovator by publications such as Forbes, Fortune, and Financial Express.
About IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.